FreeStyle Libre reader and sensor

Clinical trial results highlight the benefits of FreeStyle Libre 2 system vs self-monitoring blood glucose (SMBG)*†1-6

In clinical trials of T1D and T2D patients vs. SMBG, FreeStyle Libre 2 system was proven to*†1-6:

  • Increase monitoring frequency
  • Reduce time in hypoglycemia
  • Improve glucose control
Daily patterns graph showing patient's glucose trends

Clinical trials show increased glucose monitoring frequency with FreeStyle Libre 2 system*†‡1,2

T1D patients
(IMPACT Trial)*‡1

Increased frequency of glucose monitoring with FreeStyle Libre system

T2D patients
(REPLACE Trial)†‡2

Increased frequency of glucose monitoring with FreeStyle Libre system

FreeStyle Libre 2 system is clinically proven to reduce time spent in hypoglycemia in T1D and T2D patients vs SMBG testing‡1,2

T1D patients
(IMPACT Trial)*‡1

Reduction of time in hypoglycemia with FreeStyle Libre system

T2D patients
(REPLACE Trial)†‡2

Reduction of time in hypoglycemia with FreeStyle Libre system

FreeStyle Libre 2 system is clinically proven to reduce hypoglycemia in T1D and T2D patients with no statistically significant increase in A1c vs SMBG testing‡1,2

Reduction in hypoglycemia with FreeStyle Libre system

Exhibiting no statistically significant increase in A1c‡1,2

T1D patients
(IMPACT Trial)*‡1

Reduction of time in hypoglycemia with FreeStyle Libre system

T2D patients
(REPLACE Trial)†‡2

Reduction of time in hypoglycemia with FreeStyle Libre system

Significantly reduced hypoglycemia is sustained through the 6-month study period*†‡1,2

T1D patients
(IMPACT Trial)*‡1

Reduction of time in hypoglycemia with FreeStyle Libre system

T2D patients
(REPLACE Trial)†‡2

Reduction of time in hypoglycemia with FreeStyle Libre system

Want a sales rep to provide more information?

Talk Bubble

*IMPACT Trial: A randomized, controlled 6-month trial to evaluate the effectiveness of the FreeStyle Libre glucose monitoring system (n=119) on glycemic control for the self-management of type 1 diabetes (TlD) as compared to self-monitored blood glucose (SMBG; n=120).

REPLACE Trial: A randomized, controlled trial to evaluate the impact of the FreeStyle Libre glucose monitoring system (n=149) on HbA1c in people with type 2 diabetes (T2D) taking multiple daily doses of insulin at 6 months compared to self-monitored blood glucose (SMBG; n=75).

Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.

References: 1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked randomised controlled trial. Lancet. 2016;388(10057):2254-2263. 2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8(3):573-586. 3. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium conducted at: 78th Scientific Sessions of the American Diabetes Association; June 22-26, 2018; Orlando, FL. 4. Evans M, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1):83-95. 5. Kroeger J, Fasching P, Hanaire H. Meta-analysis of three, real-world, chart review studies to determine the effectiveness of FreeStyle Libre flash glucose monitoring system on HbA1c in adults with type 2 diabetes. Poster presented at: 79th Scientific Sessions of the American Diabetes Association; June 7-11, 2019; San Francisco, CA. 6. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46.

ADC-05530 v5.0 07/20